Blog

In a groundbreaking study poised to reshape our understanding of prostate cancer risk factors, researchers have unveiled compelling evidence linking non-insulin-based insulin resistance indices and mean platelet volume (MPV) to the incidence of prostate cancer. Published in the prestigious journal BMC Cancer, this cross-sectional analysis

In a groundbreaking advancement for the field of glycoscience, researchers have unveiled GlycoPro, a cutting-edge high-throughput platform specifically engineered for multi-glycosylation-omics analysis. This innovative technology promises to revolutionize the way scientists process and study glycosylation, a pivotal post-translational modification that influences protein structure and function.

A groundbreaking study published in the April 2025 issue of Oncotarget illuminates the complex immune dynamics within high-grade squamous intraepithelial lesions (HSILs) of the anogenital region, shedding light on the interplay between viral oncogenesis and immune evasion mechanisms. Researchers from the Instituto D’Or de Pesquisa

In the United States, approximately one in four women aged between 45 and 60 face an elevated risk of developing breast cancer, positioning them as prime candidates for preventive interventions. Among the most widely prescribed medications for reducing breast cancer risk is tamoxifen, a selective

In the relentless pursuit to uncover the underlying causes of cancer, mitochondria—those tiny powerhouses within our cells—have emerged at the forefront of scientific inquiry. Recent groundbreaking research employs Mendelian randomization (MR), a cutting-edge genetic epidemiology method, to unravel the intricate causal connections between mitochondrial function

Researchers at the University of Gothenburg have uncovered a groundbreaking mechanism by which the influenza A virus commandeers the host’s gene regulatory machinery to enhance its own replication and dissemination. Their findings, recently published in the prestigious journal Nucleic Acids Research, reveal that the virus

A groundbreaking advancement in the management of treatment-induced dermatologic toxicity has emerged from a recent clinical trial conducted at The University of Texas MD Anderson Cancer Center. This study introduces LUT014, a novel topical gel formulated to mitigate the severity of acneiform rash commonly induced

In a landmark development in the field of oncology and targeted cancer therapies, researchers at The University of Texas MD Anderson Cancer Center have unveiled compelling early-phase clinical trial data for RO7589831, a pioneering small-molecule inhibitor that represents the first-in-class therapeutic targeting Werner helicase. This

A groundbreaking study published in BMC Cancer has revealed a compelling link between thyroid dysfunction (TD) and the effectiveness of PD-1/PD-L1 inhibitors in patients battling advanced lung cancer. This new research spotlights baseline thyroid-stimulating hormone (TSH) levels as a potent predictor of immune checkpoint inhibitor

image: Visual Abstract view more  Credit: The University of Texas MD Anderson Cancer Center Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer These cancers are associated with resistance to standard therapies and poor prognosis As an oral pill, zongertinib